Prime Medicine Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
13.7%projected annual EPS growth
Analyst Coverage
10analysts covering
FY EPS (est.)
-$0.99next fiscal year
Monitoring Framework
Key Performance Indicators
Cash Runway Quarterly149.2MTarget: Sufficient to fund operations into 2027
Quarterly R&D Expenses Quarterly34.1MTarget: Disciplined capital allocation focused on in vivo liver franchise
Watch Items
- PM577 (Wilson Disease) IND/CTA FilingTrigger: Regulatory clearance of IND/CTA in H1 2026 / 2H 2026Action: Initiate Phase 1 clinical trial and prepare for first-in-human dosing
- PM647 (Alpha-1 Antitrypsin Deficiency) IND/CTA FilingTrigger: Regulatory clearance of IND/CTA in mid-2026 / 2H 2026Action: Initiate Phase 1 clinical trial and prepare for first-in-human dosing
- PM359 (Chronic Granulomatous Disease) BLA FilingTrigger: Final alignment with the FDA on accelerated approval path using two-patient proof-of-concept dataAction: Submit Biologics License Application (BLA) for PM359
Research as of 19 Jun 2026